Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Phase I data for Atu027 and Potential Fundraising

6 Jun 2012 12:00

FOR IMMEDIATE RELEASE

Silence Therapeutics Announces Safe and Effective Dose Successfully Identified

in Phase I Study of Atu027 and Potential Fund Raising

London, June 6, 2012 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, on Monday presented the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, alongside the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois. At this meeting, Klaus Giese, Ph.D., Silence's Chief Scientific Officer and the study's principal investigator Dr. Dirk Strumberg, Professor of Medicine and Director of Department of Hematology and Medical Oncology at University of Bochum (Marienhospital Herne, Germany), gave an update and discussed the data from the Atu027 Phase I trial.

Silence's open label, single-centre, dose-finding Phase I study of Atu027 in subjects with advanced solid cancer was designed to evaluate up to a total of 11 escalating doses of Atu027. The enrolment of patients in the last cohort in dose level 10 has been completed and last treatment is scheduled on 22nd of June 2012. Atu027 was very well tolerated and safe up to the 10th dose level. No premedication was needed in support of Atu027 treatment. The prospective recommended maximum tolerated dose is 0.336 mg/kg. "Stable disease" response for three and six months after treatment was observed in 10 and 3 patients, respectively, of the 33 evaluable patients. Two patients with neuroendocrine cancer had disease stabilisation for 9 and 12 months. Partial regression of pulmonary metastases was found in another patient. A further patient with breast cancer showed regression of liver metastases.

Further evaluation showed that treatment with Atu027 at dose level 8 (0.18 mg siRNA/kg) achieved the same blood plasma siRNA concentration that in preclinical studies had been sufficient to trigger silencing of PKN3 expression. Therefore, the tested dose levels 8-10 can be considered effective and safe. These data are supported by the identification of a putative biomarker. Reduction of soluble VEGF-R1 (sFLT-1) levels was observed in plasma samples from 7 out of 9 patients in dose levels 6-9 after repeated Atu027 treatment. Interestingly, the levels of soluble VEGF-R2 and soluble VEGF-R3 were not changed upon Atu027 treatment. There is evidence that sVEGF-R1 function could be a direct downstream effector of PKN3 and as such serve as a readout for biological activity.

Silence also announces that it is in advanced discussions to raise between £4-5m from new and existing shareholders to secure the funding for the Company's R&D and marketing through until 2014.

Klaus Giese, Chief Scientific Officer of Silence, commented "These are very encouraging results. We believe that PKN3 is central to the signaling pathway critical for steering cancer metastasis. The reported anti-metastatic activity, safety and tolerability of Atu027 in patients advocate for future testing of Atu027combination therapy with existing chemotherapeutic regimens. This Phase I study has laid the foundation for a novel RNAi therapeutic as a promising treatment option for cancer patients."

A copy of the ASCO presentation is available on Silence's website at http://silence-therapeutics.com/#!/news-and-events/events/

-Ends-

For further information, please contact:

Silence Therapeutics Singer Capital Markets Tony Sedgwick / Max Herrmann Shaun Dobson / Claes Sp¥ng T: +44 20 7491 6520 T: +44 20 3205 7500 a.sedgwick@silence-therapeutics.com shaun.dobson@singercm.com m.herrmann@silence-therapeutics.com claes.spang@singercm.com M:Communications Mary-Jane Elliott / Sarah Macleod / Claire Dickinson T: +44 20 7920 2330 silencetherapeutics@mcomgroup.com

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEXâ„¢, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEXâ„¢. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim safety and pharmacokinetic data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in July 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

XLON
Date   Source Headline
30th Jul 200812:00 pmPRNStatement re Update Regarding Milestone Payment
25th Jul 200810:57 amPRNHolding(s) in Company
24th Jul 20082:00 pmPRNTiming of AGM and Interim Results
24th Jul 20087:00 amPRNHolding(s) in Company
11th Jul 200812:12 pmPRNStatement re Successful Patent Opposition
1st Jul 20087:00 amPRNDirectorate Change
25th Jun 200812:30 pmPRNResearch Update
25th Jun 20087:00 amPRNAnnual Report and Accounts
24th Jun 20083:50 pmPRNHolding(s) in Company
18th Jun 20081:10 pmPRNHolding(s) in Company
9th Jun 20087:00 amRNSPresentations at upcoming con
5th Jun 20087:00 amPRNHolding(s) in Company
16th May 20082:05 pmPRNHolding(s) in Company
6th May 20089:00 amRNSPresentation at Conference
7th Apr 20084:12 pmRNSHolding(s) in Company
7th Apr 20087:01 amRNSDevelopment Concept Supported
1st Apr 20087:05 amPRNDirector/PDMR Shareholding
31st Mar 20087:49 amPRNDirector/PDMR Shareholding
27th Mar 20082:24 pmPRNHolding(s) in Company
27th Mar 20087:00 amPRNPreliminary Final Results
19th Mar 20082:30 pmPRNNotice of Results
19th Mar 200810:56 amPRNHolding(s) in Company
13th Mar 20082:15 pmPRNRe Agreement
13th Mar 200810:54 amPRNHolding(s) in Company
5th Feb 200811:00 amPRNHolding(s) in Company
31st Jan 20084:25 pmPRNHolding(s) in Company
30th Jan 20087:00 amPRNHolding(s) in Company
23rd Jan 200810:05 amPRNHolding(s) in Company
21st Jan 20084:09 pmPRNHolding(s) in Company
17th Jan 20087:00 amPRNHolding(s) in Company
7th Jan 20087:00 amPRNStatement re Chairman's Letter to Shareholders
2nd Jan 20084:25 pmPRNHolding(s) in Company
2nd Jan 200811:10 amPRNHolding(s) in Company
24th Dec 20077:00 amPRNDirector/PDMR Shareholding
17th Dec 20071:40 pmPRNStatement re Share Price Movement
14th Dec 20074:20 pmPRNHolding(s) in Company
12th Dec 20071:31 pmPRNHolding(s) in Company
4th Dec 20074:23 pmPRNHolding(s) in Company
26th Nov 20074:21 pmPRNHolding(s) in Company
23rd Nov 20073:30 pmPRNHolding(s) in Company
20th Nov 20077:00 amPRNChange of Nomad
19th Nov 20071:00 pmPRNResearch Update
19th Nov 20077:02 amRNSPresentation at Conference
5th Nov 20071:20 pmPRNHolding(s) in Company
2nd Nov 200712:35 pmPRNHolding(s) in Company
2nd Nov 20077:01 amRNSConference Attendance
30th Oct 200710:00 amPRNHolding(s) in Company
29th Oct 20074:15 pmPRNHolding(s) in Company
26th Oct 20074:15 pmPRNHolding(s) in Company
25th Oct 200711:10 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.